ORCID Profile
0000-0003-0556-4406
Current Organisations
AVON RIDGE EQUINE VETERINARY SERVICES
,
Murdoch University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 15-05-2023
DOI: 10.1111/EVJ.13944
Publisher: Wiley
Date: 07-09-2023
DOI: 10.1111/EVJ.13997
Publisher: Wiley
Date: 17-11-2022
DOI: 10.1111/EVE.13738
Abstract: Hyperinsulinaemia‐associated laminitis (HAL) is encountered commonly in equine practice. There are currently no registered medications which specifically target hyperinsulinaemia in horses and ponies. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to limit post‐prandial insulin responses and prevent the development of diet‐induced laminitis. The objective of the study was to evaluate the efficacy of an SGLT2i, ertugliflozin, in the management of hyperinsulinaemia and laminitis. Retrospective case series. Medical records of 51 horses and ponies that had presented with laminitis and hyperinsulinaemia and had been treated with oral ertugliflozin at 0.05 mg/kg once daily for a minimum of 30 days were reviewed. After 30 days of treatment with ertugliflozin, there was a reduction in insulin concentrations from a median of μu/ml (IQR: 149, ) to 43 μu/ml (IQR: 20, 66) ( p 0.001). Modified Obel laminitis scores improved, reducing from a median of 10/12 to 1/12 ( p 0.001). Median serum triglyceride concentrations increased from 0.6 (IQR: 0.4, 0.9) before treatment to 1.4 (IQR: 0.8, 3.7) mmol/L after 30 days of treatment ( p 0.001) before declining, however, none of the horses developed any clinical signs of hyperlipaemia. Ten horses (19%) were reported to have polyuria and polydipsia during treatment, otherwise no adverse clinical effects were identified. The study was limited by the absence of a control group, the retrospective data collection and the short period of follow‐up. Ertugliflozin may be effective in reducing insulin concentrations in horses and ponies with equine metabolic syndrome and its use may hasten recovery from laminitis associated with hyperinsulinaemia.
Publisher: Wiley
Date: 19-04-2023
DOI: 10.1111/EVJ.13938
Abstract: An extended‐release injectable omeprazole formulation (ERIO) has become a popular treatment for equine squamous gastric disease (ESGD) and equine glandular gastric disease (EGGD) where it is available however, published data are limited and optimal treatment regimens have not been determined. To compare effects of treatment on ESGD and EGGD when an ERIO formulation is administered at either 5‐ or 7‐day intervals. Retrospective clinical study. Case records and gastroscopy images of horses with ESGD or EGGD treated with ERIO were reviewed. Images were anonymised and graded by one researcher masked to treatment group. Treatment responses were compared between the two treatment schedules using univariable ordered logistic regression. Forty‐three horses were treated with ERIO at 5‐day intervals and 39 horses at 7‐day intervals. Signalment and presenting signs did not differ between groups. The proportions of horses with EGGD healing (to grade 0 or 1) in association with ERIO used at 5‐day intervals (93%) were higher than associated with treatment at 7‐day intervals (69% odds ratio [OR]: 2.41, 95% CI: 1.23–4.74, p = 0.01). For ESGD, there was no significant difference in the proportion of horses healing in association with treatment at 5‐day intervals (97%) compared with 7‐day intervals (82% OR: 2.75, 95% CI: 0.91–8.31, p = 0.07). Four of 328 injections were associated with an injection‐site reaction (1%). Retrospective study design, lack of randomisation and limited case numbers. The use of ERIO at 5‐day intervals might be more appropriate than the 7‐day interval that is used currently.
Publisher: Authorea, Inc.
Date: 20-09-2023
No related grants have been discovered for Tania Sundra.